Article
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2008
Chin Tan Min, Quinlan Margaret P, Singh Anurag, Sequist Lecia V, Lynch Thomas J, Haber Daniel A, Sharma Sreenath V, Settleman Jeffrey
Abstract excerpt
PURPOSE: Epidermal growth factor receptor (EGFR) kinase inhibitors induce dramatic clinical responses in a subset of non-small cell lung cancer (NSCLC) patients with advanced disease, and such responses are correlated with the presence of somatic activating mutations within the EGFR kinase domain...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.